Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsA structure-based model for predicting serum albumin bindingThe bioanalytical challenge of determining unbound concentration and protein binding for drugs.The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein bindingCharacterization of plasma protein binding dissociation with online SPE-HPLC.A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of DoxorubicinA simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuseFormation of stable nanocarriers by in situ ion pairing during block-copolymer-directed rapid precipitationContribution of Amphipathicity and Hydrophobicity to the Antimicrobial Activity and Cytotoxicity of β-Hairpin PeptidesNitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.The significance of acid/base properties in drug discoveryThe unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis.Protein engineering: a new frontier for biological therapeutics.Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier.A Comparison of LC-MS/MS and a Fully Integrated Autosampler/Solid-Phase Extraction System for the Analysis of Protein Binding Samples.A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compoundsThe Binding Effect of Proteins on Medications and Its Impact on Electrochemical Sensing: Antipsychotic Clozapine as a Case Study.Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite).Plasma protein binding monitoring of therapeutic drugs in patients using single set of hollow fiber centrifugal ultrafiltration.A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences.New diketopiperazines as vectors for peptide protection and brain delivery: Synthesis and biological evaluation.Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone.Nonlinear Protein Binding: Not What You Think.Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood.Development of a Dynamic Physiologically Based Mechanistic Kidney Model to Predict Renal Clearance
P2860
Q26827380-4FA8C2CD-E036-41AB-88A0-72748CE78CDAQ28541718-A3D5B84E-B8AE-43DF-9989-9AD9843B90A8Q35062663-3E127D04-A6C9-4442-B317-68223AB32403Q35186490-6BE0E2D7-B6D0-4EA6-A93A-CCD334D7DD10Q36149937-C5CFE06D-DA68-4663-BE3D-AD0A09D4D370Q36446685-9575F50D-4A9D-4C36-90F1-15AD78256BBAQ36480112-7FA68162-CC00-43D8-B7E5-0196812FB0A1Q36916351-9DD372FF-BEFC-4AD4-B79E-D7481F291A55Q37000571-EE26A78F-382E-4D55-B560-8A1DF02E4280Q37037261-6200B525-7B4F-4BD8-93F8-9A35CFE1AAB4Q38055676-C31C19EB-617C-460E-BC79-AAAE0AB5934CQ38192568-EE7FA0EA-3FF0-408D-8266-8D28824D7AE7Q38286271-4622791F-1FA4-4621-A5A4-CCD86F7AD5B5Q38846048-B1297B1D-BF35-4024-9627-4B551C7786F5Q39746291-D98FF1D5-3FB7-43E7-B99E-A596808BB0EBQ39977756-5D9D8B40-B22A-476A-A360-055B86FEF5DBQ41761907-B79B7A8C-105C-4030-AAE1-EF5C0DA19D3CQ42366878-5FD95E3D-14A8-448A-AA86-320713725F89Q47133712-DB1F8808-B0BD-4033-87FF-EB71E39AF5FDQ47935103-7FE20EF4-5291-4FE9-8240-8BA05DA34318Q47963518-146CE06E-B7B5-421E-AD30-2902E45F1589Q48225243-6A8D5CD1-2480-4594-BA24-C359D37627BFQ48362481-AC34C778-2A65-4508-BEA8-DCDBF954C1D5Q50755572-85852E30-2920-4E02-822B-4ABDE20CC860Q50927547-1A7C5F96-B2DE-4B76-A07C-C6C010DF26CBQ52601413-7E86B772-93B2-4E25-AA89-61B01A737618Q54983489-83A82EFC-E457-4E86-A32B-5CAB11070B67Q58788134-AD392409-DC55-425A-BD46-510C82E3CE8A
P2860
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@ast
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@en
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@nl
type
label
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@ast
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@en
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@nl
prefLabel
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@ast
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@en
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@nl
P2093
P1433
P1476
Compilation of 222 drugs' plasma protein binding data and guidance for study designs.
@en
P2093
Fengling Zhang
Jingwei Shao
Jinpin Xue
P304
P356
10.1016/J.DRUDIS.2011.12.018
P577
2011-12-23T00:00:00Z